Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity

Cancer immunotherapy, largely represented by immune checkpoint inhibitors (ICI), has led to substantial changes in preclinical cancer research and clinical oncology practice over the past decade. However, the efficacy and toxicity profiles of ICIs remain highly variable among patients, with only a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzutilo, Elio Gregory, Romanò, Rebecca, Roazzi, Laura, Agostara, Alberto G., Oresti, Sara, Zeppellini, Annalisa, Giannetta, Laura, Cerea, Giulio, Signorelli, Diego, Siena, Salvatore, Sartore-Bianchi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345966/
https://www.ncbi.nlm.nih.gov/pubmed/37205627
http://dx.doi.org/10.1158/0008-5472.CAN-23-0161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345966/
https://www.ncbi.nlm.nih.gov/pubmed/37205627
http://dx.doi.org/10.1158/0008-5472.CAN-23-0161

Ejemplares similares